Vol. 1 · Issue 3 · April 19, 2026 Free weekly · Evidence-based
Subscribe free
Independent medical journal review
CliniScope Weekly

One peer-reviewed article. One honest take. Every week.

This week's review
Clinical

Empagliflozin Started Within 72 Hours of a Heart Attack Improved Cardiac Biomarkers and Echocardiographic Parameters at 26 Weeks

von Lewinski D, Kolesnik E, Tripolt NJ, et al.

European Heart Journal · April 19, 2026 · 8 min read

The EMMY trial found that empagliflozin started within 72 hours of large acute MI improved NT-proBNP and echocardiographic parameters at 26 weeks — but the subsequent EMPACT-MI trial did not show a reduction in hard clinical outcomes.

Read this week's review →
Key numbers
476
Patients enrolled
15%
NT-proBNP reduction
1.5%
LVEF improvement
26 weeks
Follow-up

"Empagliflozin started within 72 hours of a heart attack improved cardiac biomarkers and echocardiographic parameters at 26 weeks. Whether that improvement translates to fewer hospitalizations and deaths is a different question, and a harder one."

— CliniScope Weekly, Vol. 1 Issue 3
Recent reviews
Clinical

Empagliflozin Started Within 72 Hours of a Heart Attack Improved Cardiac Biomarkers and Echocardiographic Parameters at 26 Weeks

European Heart Journal

Emerging Research

A Systematic Review of 30 Studies Found That Large Language Models Can Match or Outperform Clinicians on Structured Diagnostic Tasks

JMIR Medical Informatics

Epidemiology

Nine Years of Progress in Cardiovascular Mortality Were Reversed Between 2019 and 2022

American Journal of Preventive Medicine

Clinical

Empagliflozin Started Within 72 Hours of a Heart Attack Improved Cardiac Biomarkers and Echocardiographic Parameters at 26 Weeks

European Heart Journal

Emerging Research

A Systematic Review of 30 Studies Found That Large Language Models Can Match or Outperform Clinicians on Structured Diagnostic Tasks

JMIR Medical Informatics

Epidemiology

Nine Years of Progress in Cardiovascular Mortality Were Reversed Between 2019 and 2022

American Journal of Preventive Medicine

Clinical

Empagliflozin Started Within 72 Hours of a Heart Attack Improved Cardiac Biomarkers and Echocardiographic Parameters at 26 Weeks

European Heart Journal

Emerging Research

A Systematic Review of 30 Studies Found That Large Language Models Can Match or Outperform Clinicians on Structured Diagnostic Tasks

JMIR Medical Informatics

Epidemiology

Nine Years of Progress in Cardiovascular Mortality Were Reversed Between 2019 and 2022

American Journal of Preventive Medicine

Clinical

Empagliflozin Started Within 72 Hours of a Heart Attack Improved Cardiac Biomarkers and Echocardiographic Parameters at 26 Weeks

European Heart Journal

Emerging Research

A Systematic Review of 30 Studies Found That Large Language Models Can Match or Outperform Clinicians on Structured Diagnostic Tasks

JMIR Medical Informatics

Epidemiology

Nine Years of Progress in Cardiovascular Mortality Were Reversed Between 2019 and 2022

American Journal of Preventive Medicine

Editor's research & publications

Selected peer-reviewed publications and book contributions authored by Kameron Farhadi across clinical epidemiology, public health, and dentistry.

8
Publications
3
Research domains
1
Book chapter
9
Presentations
About the editor
Kameron Farhadi

Editor & founder

Kameron Farhadi

Former Dental Student · Pre-Medical Student · Researcher

CliniScope Weekly exists because the gap between medical research and clinical understanding is too wide. Each review translates one peer-reviewed study into something a pre-medical student and a seasoned attending can both learn from. Kameron's work spans 8 publications across clinical epidemiology, public health, and health policy — including one peer-reviewed textbook chapter.

8
Publications
3
Domains
1
Book chapter
9
Presentations
EpidemiologyImplantologyPreventive MedicineHealth EquityPopulation Health

Free · Weekly · No spam

One article. One take. Every Sunday.

Get each week's review delivered to your inbox — no subscriptions, no paywalls.

cliniscopeweekly.com · Unsubscribe anytime